Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
T127425-250mg | 250mg | In stock | $21.90 | |
T127425-500mg | 500mg | In stock | $34.90 | |
T127425-1g | 1g | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $47.90 | |
T127425-5g | 5g | In stock | $142.90 | |
T127425-25g | 25g | In stock | $426.90 |
DNA alkylating/methylating chemotherapeutic agent
Synonyms | 4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide | CCRG 81045 | NSC 362856 | TMZ | 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide | 8-Carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one | TZM |
---|---|
Specifications & Purity | Moligand™, ≥98%(HPLC) |
Biochemical and Physiological Mechanisms | enzyme. Research has also been conducted to determine whether MGMT inhibitors such as O-6-benzylguanine might help to increase the efficacy of temozolomide. Furthermore, temozolomide has been implicated in causing arrest at the G2/M cell cycle checkpoint, |
Storage Temp | Store at 2-8°C,Argon charged |
Shipped In | Wet ice |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | DNA inhibitor |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Temozolomide is a DNA damage inducer. |
ALogP | -1.1 |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide |
---|---|
INCHI | InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13) |
InChi Key | BPEGJWRSRHCHSN-UHFFFAOYSA-N |
Canonical SMILES | CN1C(=O)N2C=NC(=C2N=N1)C(=O)N |
Isomeric SMILES | CN1C(=O)N2C=NC(=C2N=N1)C(=O)N |
WGK Germany | 3 |
RTECS | NJ5927050 |
PubChem CID | 5394 |
Molecular Weight | 194.15 |
Reaxy-Rn | 5547136 |
DrugBank Ligand | DB00853 |
---|---|
PubChem CID | 5394 |
CAS Registry No. | 85622-93-1 |
ChEMBL Ligand | CHEMBL810 |
Wikipedia | Temozolomide |
PEP | temozolomide |
DrugCentral Ligand | 2589 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
I2412042 | Certificate of Analysis | Sep 21, 2024 | T127425 |
I2412043 | Certificate of Analysis | Sep 18, 2024 | T127425 |
J2410764 | Certificate of Analysis | Sep 04, 2024 | T127425 |
J2410763 | Certificate of Analysis | Sep 04, 2024 | T127425 |
J2410762 | Certificate of Analysis | Sep 04, 2024 | T127425 |
J2410761 | Certificate of Analysis | Sep 04, 2024 | T127425 |
J2227766 | Certificate of Analysis | Aug 15, 2024 | T127425 |
J2227749 | Certificate of Analysis | Aug 15, 2024 | T127425 |
J2227698 | Certificate of Analysis | Aug 12, 2024 | T127425 |
J2227785 | Certificate of Analysis | Aug 12, 2024 | T127425 |
J2227652 | Certificate of Analysis | Aug 12, 2024 | T127425 |
F2217267 | Certificate of Analysis | Apr 02, 2024 | T127425 |
D2408191 | Certificate of Analysis | Mar 22, 2024 | T127425 |
I1817142 | Certificate of Analysis | Feb 26, 2024 | T127425 |
K2130080 | Certificate of Analysis | Sep 15, 2023 | T127425 |
K2130076 | Certificate of Analysis | Sep 15, 2023 | T127425 |
K2130077 | Certificate of Analysis | Sep 15, 2023 | T127425 |
K2130078 | Certificate of Analysis | Sep 15, 2023 | T127425 |
J2227772 | Certificate of Analysis | Jul 21, 2022 | T127425 |
D2409062 | Certificate of Analysis | Jul 21, 2022 | T127425 |
A2408039 | Certificate of Analysis | Jul 21, 2022 | T127425 |
C2221050 | Certificate of Analysis | Mar 24, 2022 | T127425 |
Solubility | Soluble in water (5 mg/ml at 25 °C), DMSO (39 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C). |
---|---|
Sensitivity | Heat sensitive |
Melt Point(°C) | 206 °C(dec.) |
Pictogram(s) | GHS06, GHS08, GHS07 |
---|---|
Signal | Danger |
Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation H335:May cause respiratory irritation H341:Suspected of causing genetic defects H351:Suspected of causing cancer H302:Harmful if swallowed H300:Fatal if swallowed H372:Causes damage to organs through prolonged or repeated exposure H360:May damage fertility or the unborn child H340:May cause genetic defects H350:May cause cancer |
Precautionary Statements | P261:Avoid breathing dust/fume/gas/mist/vapors/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P281:Use personal protective equipment as required. P271:Use only outdoors or in a well-ventilated area. P270:Do not eat, drink or smoke when using this product. P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing. P403+P233:Store in a well-ventilated place. Keep container tightly closed. P362+P364:Take off contaminated clothing and wash it before reuse. P330:Rinse mouth. P203:Obtain, read and follow all safety instructions before use. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P301+P316:IF SWALLOWED: Get emergency medical help immediately. P301+P317:IF SWALLOWED: Get medical help. P318:if exposed or concerned, get medical advice. P337+P317:If eye irritation persists: Get medical help. P332+P317:If skin irritation occurs: Get medical help. P319:Get medical help if you feel unwell. |
WGK Germany | 3 |
RTECS | NJ5927050 |
Reaxy-Rn | 5547136 |
Merck Index | 9139 |
Starting at $52.90
1. Yechun Jiang, Yu Jin, Chengcheng Feng, Yayun Wu, Weinan Zhang, Liang Xiao, Zhaoyou Chu, Benjin Chen, Yan Ma, Haisheng Qian, Lingling Xu. (2023) Engineering Hyaluronic Acid Microneedles Loaded with Mn2+ and Temozolomide for Topical Precision Therapy of Melanoma. Advanced Healthcare Materials, (2303215). [PMID:38112062] [10.1002/adhm.202303215] |
2. Li Yatian, Gao Zhenyue, Wang Yuhong, Pang Bo, Zhang Binbin, Hu Ruxin, Wang Yuqing, Liu Chao, Zhang Xuebin, Yang Jingxuan, Mei Mei, Wang Yongzhi, Zhou Xuan, Li Min, Ren Yu. (2023) Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma. Nature Communications, 14 (1): (1-19). [PMID:37429858] [10.1038/s41467-023-39845-z] |
3. Yajing Wang, Ziwei Ding, Shiqun Lv, Jie Liu, Jie Pan, Yingcong Yu, Jun Gao, Xianfeng Huang. (2023) Development of tLyP-1 functionalized nanoliposomes with tunable internal water phase for glioma targeting. JOURNAL OF LIPOSOME RESEARCH, [PMID:36974836] [10.1080/08982104.2023.2191718] |
4. Hou Xiaoying, Du Hongzhi, Deng Yufei, Wang Haiping, Liu Jinmi, Qiao Jialu, Liu Wei, Shu Xiji, Sun Binlian, Liu Yuchen. (2023) Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma. Journal of Translational Medicine, 21 (1): (1-15). [PMID:36927689] [10.1186/s12967-023-04042-5] |
5. Xiaoyi Shi, Meng Li, Qiming Huang, Liuming Xie, Zhibing Huang. (2023) Monacolin K Induces Apoptosis of Human Glioma U251 Cells by Triggering ROS-Mediated Oxidative Damage and Regulating MAPKs and NF-κB Pathways. ACS Chemical Neuroscience, 14 (7): (1331–1341). [PMID:36917811] [10.1021/acschemneuro.3c00104] |
6. Su Jie, Yin Wei, Huo Mengmeng, Yao Qing, Ding Liqiong. (2023) Induction of apoptosis in glioma cells by lycorine via reactive oxygen species generation and regulation of NF-κB pathways. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 396 (6): (1247-1255). [PMID:36715733] [10.1007/s00210-023-02384-x] |
7. Zhou Songlei, Huang Yukun, Chen Yu, Liu Yipu, Xie Laozhi, You Yang, Tong Shiqiang, Xu Jianpei, Jiang Gan, Song Qingxiang, Mei Ni, Ma Fenfen, Gao Xiaoling, Chen Hongzhuan, Chen Jun. (2023) Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma. Nature Communications, 14 (1): (1-20). [PMID:36702831] [10.1038/s41467-023-35957-8] |
8. Chen Bo, Li Xiaoli, Wu Lihong, Zhou Duanfang, Song Yi, Zhang Limei, Wu Qiuya, He Qichen, Wang Gang, Liu Xu, Hu Hui, Zhou Weiying. (2022) Quercetin Suppresses Human Glioblastoma Migration and Invasion via GSK3β/β-catenin/ZEB1 Signaling Pathway. Frontiers in Pharmacology, 13 (4678). [PMID:36386155] [10.3389/fphar.2022.963614] |
9. Hu Keqi, Zhou Daquan, Rao Linlin, Wang Peng, Xiang Chunxiang, Chen Feng. (2021) A Multifunctional AIE Nanoprobe as a Drug Delivery Bioimaging and Cancer Treatment System. Frontiers in Bioengineering and Biotechnology, 9 (1034). [PMID:34820365] [10.3389/fbioe.2021.766470] |
10. Mingming Sun, Hao Sheng, Tingfeng Wu, Jiaqi Song, Huanran Sun, Yingzhi Wang, Jiyan Wang, Zhen Li, Huifang Zhao, Junzhen Tan, Yanping Li, Guo Chen, Qingrong Huang, Yuan Zhang, Bei Lan, Shuangping Liu, Changliang Shan, Shuai Zhang. (2021) PIKE-A promotes glioblastoma growth by driving PPP flux through increasing G6PD expression mediated by phosphorylation of STAT3. BIOCHEMICAL PHARMACOLOGY, 192 (114736). [PMID:34411567] [10.1016/j.bcp.2021.114736] |
11. Man Xu, Guangmeng Li, Haoxiang Zhang, Xiaoming Chen, Yi Li, Qianming Yao, Maobin Xie. (2020) Sequential delivery of dual drugs with nanostructured lipid carriers for improving synergistic tumor treatment effect. DRUG DELIVERY, 27 (1): (983-995). [PMID:32611218] [10.1080/10717544.2020.1785581] |
12. Zeng Xiaofan, Wang Qi, Tan Xuan, Jia Le, Li Yuwei, Hu Mingdi, Zhang Zhijie, Bai Xicheng, Zhu Yanhong, Yang Xiangliang. (2019) Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma. JOURNAL OF NANOBIOTECHNOLOGY, 17 (1): (1-12). [PMID:30935403] [10.1186/s12951-019-0483-1] |
13. Yuanyuan Xie, Xiaofan Zeng, Xian Wu, Jun Hu, Yanhong Zhu, Xiangliang Yang. (2018) Hyperbaric oxygen as an adjuvant to temozolomide nanoparticle inhibits glioma growth by inducing G2/M phase arrest. Nanomedicine, [PMID:29473458] [10.2217/nnm-2017-0395] |
14. Bin Du, Changqing Hong, Xinghong Zhang, Jiazhi Wang, Qiang Qu. (2018) Preparation and mechanical behaviors of SiOC-modified carbon-bonded carbon fiber composite with in-situ growth of three-dimensional SiC nanowires. JOURNAL OF THE EUROPEAN CERAMIC SOCIETY, 38 (2272). [PMID:] [10.1016/j.jeurceramsoc.2018.01.002] |
15. Yao‑Dong Chen, Yu Zhang, Tian‑Xiu Dong, Yu‑Tong Xu, Wei Zhang, Ting‑Ting An, Peng‑Fei Liu, Xiu‑Hua Yang. (2017) Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells. Molecular Medicine Reports, 16 (6): (9401-9408). [PMID:29039593] [10.3892/mmr.2017.7769] |
16. Qicheng Chen, Li Ye, Jiajun Fan, Xuyao Zhang, Huan Wang, Siyang Liao, Ping Song, Ziyu Wang, Shaofei Wang, Yubin Li, Jingyun Luan, Yichen Wang, Wei Chen, Wenjing Zai, Ping Yang, Zhonglian Cao, Dianwen Ju. (2017) Autophagy suppression potentiates the anti-glioblastoma effect of asparaginase in vitro and in vivo. Oncotarget, 8 (53): ( 91052–91066). [PMID:29207624] [10.18632/oncotarget.19409] |
17. Nan Wang, Pei Sun, Mingming Lv, Gangsheng Tong, Xin Jin, Xinyuan Zhu. (2017) Mustard-inspired delivery shuttle for enhanced blood–brain barrier penetration and effective drug delivery in glioma therapy. Biomaterials Science, 5 (5): (1041-1050). [PMID:28378865] [10.1039/C7BM00133A] |
1. Yu J et al.. (2022) SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy.. Bioengineered, 13 (6): (14125-14137). [PMID:35730472] |
2. Yechun Jiang, Yu Jin, Chengcheng Feng, Yayun Wu, Weinan Zhang, Liang Xiao, Zhaoyou Chu, Benjin Chen, Yan Ma, Haisheng Qian, Lingling Xu. (2023) Engineering Hyaluronic Acid Microneedles Loaded with Mn2+ and Temozolomide for Topical Precision Therapy of Melanoma. Advanced Healthcare Materials, (2303215). [PMID:38112062] [10.1002/adhm.202303215] |
3. Li Yatian, Gao Zhenyue, Wang Yuhong, Pang Bo, Zhang Binbin, Hu Ruxin, Wang Yuqing, Liu Chao, Zhang Xuebin, Yang Jingxuan, Mei Mei, Wang Yongzhi, Zhou Xuan, Li Min, Ren Yu. (2023) Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma. Nature Communications, 14 (1): (1-19). [PMID:37429858] [10.1038/s41467-023-39845-z] |
4. Yajing Wang, Ziwei Ding, Shiqun Lv, Jie Liu, Jie Pan, Yingcong Yu, Jun Gao, Xianfeng Huang. (2023) Development of tLyP-1 functionalized nanoliposomes with tunable internal water phase for glioma targeting. JOURNAL OF LIPOSOME RESEARCH, [PMID:36974836] [10.1080/08982104.2023.2191718] |
5. Hou Xiaoying, Du Hongzhi, Deng Yufei, Wang Haiping, Liu Jinmi, Qiao Jialu, Liu Wei, Shu Xiji, Sun Binlian, Liu Yuchen. (2023) Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma. Journal of Translational Medicine, 21 (1): (1-15). [PMID:36927689] [10.1186/s12967-023-04042-5] |
6. Xiaoyi Shi, Meng Li, Qiming Huang, Liuming Xie, Zhibing Huang. (2023) Monacolin K Induces Apoptosis of Human Glioma U251 Cells by Triggering ROS-Mediated Oxidative Damage and Regulating MAPKs and NF-κB Pathways. ACS Chemical Neuroscience, 14 (7): (1331–1341). [PMID:36917811] [10.1021/acschemneuro.3c00104] |
7. Su Jie, Yin Wei, Huo Mengmeng, Yao Qing, Ding Liqiong. (2023) Induction of apoptosis in glioma cells by lycorine via reactive oxygen species generation and regulation of NF-κB pathways. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 396 (6): (1247-1255). [PMID:36715733] [10.1007/s00210-023-02384-x] |
8. Zhou Songlei, Huang Yukun, Chen Yu, Liu Yipu, Xie Laozhi, You Yang, Tong Shiqiang, Xu Jianpei, Jiang Gan, Song Qingxiang, Mei Ni, Ma Fenfen, Gao Xiaoling, Chen Hongzhuan, Chen Jun. (2023) Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma. Nature Communications, 14 (1): (1-20). [PMID:36702831] [10.1038/s41467-023-35957-8] |
9. Chen Bo, Li Xiaoli, Wu Lihong, Zhou Duanfang, Song Yi, Zhang Limei, Wu Qiuya, He Qichen, Wang Gang, Liu Xu, Hu Hui, Zhou Weiying. (2022) Quercetin Suppresses Human Glioblastoma Migration and Invasion via GSK3β/β-catenin/ZEB1 Signaling Pathway. Frontiers in Pharmacology, 13 (4678). [PMID:36386155] [10.3389/fphar.2022.963614] |
10. Hu Keqi, Zhou Daquan, Rao Linlin, Wang Peng, Xiang Chunxiang, Chen Feng. (2021) A Multifunctional AIE Nanoprobe as a Drug Delivery Bioimaging and Cancer Treatment System. Frontiers in Bioengineering and Biotechnology, 9 (1034). [PMID:34820365] [10.3389/fbioe.2021.766470] |
11. Mingming Sun, Hao Sheng, Tingfeng Wu, Jiaqi Song, Huanran Sun, Yingzhi Wang, Jiyan Wang, Zhen Li, Huifang Zhao, Junzhen Tan, Yanping Li, Guo Chen, Qingrong Huang, Yuan Zhang, Bei Lan, Shuangping Liu, Changliang Shan, Shuai Zhang. (2021) PIKE-A promotes glioblastoma growth by driving PPP flux through increasing G6PD expression mediated by phosphorylation of STAT3. BIOCHEMICAL PHARMACOLOGY, 192 (114736). [PMID:34411567] [10.1016/j.bcp.2021.114736] |
12. Man Xu, Guangmeng Li, Haoxiang Zhang, Xiaoming Chen, Yi Li, Qianming Yao, Maobin Xie. (2020) Sequential delivery of dual drugs with nanostructured lipid carriers for improving synergistic tumor treatment effect. DRUG DELIVERY, 27 (1): (983-995). [PMID:32611218] [10.1080/10717544.2020.1785581] |
13. Zeng Xiaofan, Wang Qi, Tan Xuan, Jia Le, Li Yuwei, Hu Mingdi, Zhang Zhijie, Bai Xicheng, Zhu Yanhong, Yang Xiangliang. (2019) Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma. JOURNAL OF NANOBIOTECHNOLOGY, 17 (1): (1-12). [PMID:30935403] [10.1186/s12951-019-0483-1] |
14. Yuanyuan Xie, Xiaofan Zeng, Xian Wu, Jun Hu, Yanhong Zhu, Xiangliang Yang. (2018) Hyperbaric oxygen as an adjuvant to temozolomide nanoparticle inhibits glioma growth by inducing G2/M phase arrest. Nanomedicine, [PMID:29473458] [10.2217/nnm-2017-0395] |
15. Bin Du, Changqing Hong, Xinghong Zhang, Jiazhi Wang, Qiang Qu. (2018) Preparation and mechanical behaviors of SiOC-modified carbon-bonded carbon fiber composite with in-situ growth of three-dimensional SiC nanowires. JOURNAL OF THE EUROPEAN CERAMIC SOCIETY, 38 (2272). [PMID:] [10.1016/j.jeurceramsoc.2018.01.002] |
16. Yao‑Dong Chen, Yu Zhang, Tian‑Xiu Dong, Yu‑Tong Xu, Wei Zhang, Ting‑Ting An, Peng‑Fei Liu, Xiu‑Hua Yang. (2017) Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells. Molecular Medicine Reports, 16 (6): (9401-9408). [PMID:29039593] [10.3892/mmr.2017.7769] |
17. Qicheng Chen, Li Ye, Jiajun Fan, Xuyao Zhang, Huan Wang, Siyang Liao, Ping Song, Ziyu Wang, Shaofei Wang, Yubin Li, Jingyun Luan, Yichen Wang, Wei Chen, Wenjing Zai, Ping Yang, Zhonglian Cao, Dianwen Ju. (2017) Autophagy suppression potentiates the anti-glioblastoma effect of asparaginase in vitro and in vivo. Oncotarget, 8 (53): ( 91052–91066). [PMID:29207624] [10.18632/oncotarget.19409] |
18. Nan Wang, Pei Sun, Mingming Lv, Gangsheng Tong, Xin Jin, Xinyuan Zhu. (2017) Mustard-inspired delivery shuttle for enhanced blood–brain barrier penetration and effective drug delivery in glioma therapy. Biomaterials Science, 5 (5): (1041-1050). [PMID:28378865] [10.1039/C7BM00133A] |